2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow AVE1642: new trials by email Literature Review of AVE1642 trials Research Report on AVE1642
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma AVE1642, sorafenib, erlotinib - Liver Carcinoma | Phase 1 / Phase 2 | Terminated | Sanofi | 13 | 2008-11-01 | 2010-08-04 |
| Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer AVE1642, Fulvestrant - Breast Neoplasms | Phase 2 | Terminated | Sanofi | 18 | 2008-10-01 | 2011-03-03 |
Breast Neoplasms (1) · Carcinoma, Hepatocellular (1)
Sanofi (2)
France (2) · Italy (1) · Spain (1)